(+)-pinanediol | 57022-61-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (+)-pinanediol
• 英文别名: (1S,2S,3R,5S)-6,6-dimethylbicyclo[3.1.1]heptane-2,3-diol
• CAS: 57022-61-4；57022-63-6
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: IOWDWNAUUOXDKM-OSMVPFSASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  异丁基硼酸 、 (+)-pinanediol 以 乙醚 为溶剂， 反应 23.0h， 以97.2%的产率得到(2-甲基丙基)硼酸(1S,2S,3R,5S)-(+)-2,3-蒎烷二醇酯
  参考文献：
  名称：

  [EN] METHODS FOR PREPARING BORTEZOMIB AND INTERMEDIATES USED IN ITS MANUFACTURE
  [FR] PROCÉDÉ DE PRÉPARATION DU BORTÉZOMIB ET INTERMÉDIAIRES UTILISÉS DANS SA PRÉPARATION

  摘要：

  本文提供了制备硼替佐米及在制备硼替佐米过程中有用的中间体的方法。目前的方法意外地提供了硼替佐米和用于制备硼替佐米的中间体的优越产量和纯度，包括光学纯度。

  公开号：

  WO2009004350A1

文献信息

• [EN] BORONIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS D'ACIDE BORONIQUE
  申请人：MERCK PATENT GMBH

  公开号：WO2016050358A1

  公开（公告）日：2016-04-07

  Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmue disorder or hematological malignancies.

  式(I)的化合物是LMP7的抑制剂，可用于治疗自身免疫性疾病或血液恶性肿瘤，等等。
• A Study of Transesterification of Chiral (−)-Pinanediol Methylboronic Ester with Various Structurally Modified Diols
  作者：Chandra D. Roy、Herbert C. Brown

  DOI：10.1007/s00706-007-0681-7

  日期：2007.8

  The transesterification of chiral (−)-pinanediol methylboronic ester was studied with various structurally modified diols by 1H NMR to understand the factors influencing the unusual stability of this boronic ester as well as to find ways of recovering pinanediol from its methylboronic ester. In all the cases, reactions were allowed to proceed to equilibrium. The preliminary experiments indeed have

  通过各种结构改性的二醇，通过1 H NMR研究了手性（-）-with烷二醇甲基硼酸酯的酯交换反应，以了解影响该硼酸酯异常稳定性的因素，并找到从其甲基硼酸酯中回收pin二醇的方法。在所有情况下，使反应进行到平衡。初步实验确实显示了一些令人鼓舞的结果（pin烷二醇的取代率高达40-53％）。在基于环戊烷的 顺式 -1,2-二醇中， 内 -2-苯基 -exo ， exo -2,3-降冰片烷二醇似乎是取代pin烷二醇最有效的二醇（38％）。在基于pin烷的二醇的情况下，使用2-乙基-6,6-二甲基双环[3.1.1]庚烷- 顺式 -2,3-二醇（53％）可获得最佳结果 。有趣的是，观察到与2-苯基-6,6-二甲基双环[3.1.1]庚烷- 顺式 -2,3-二醇的酯交换反应 仅在4天后即可产生50％的转化率，而前一个二醇则需要24天达到平衡。
• Further characterization of a putative serine protease contributing to the γ-secretase cleavage of β-amyloid precursor protein
  作者：Marine Peuchmaur、Marie-Agnès Lacour、Jean Sévalle、Vincent Lisowski、Youness Touati-Jallabe、Fabien Rodier、Jean Martinez、Frédéric Checler、Jean-François Hernandez

  DOI：10.1016/j.bmc.2012.11.045

  日期：2013.2

  The 3-alkoxy-7-amino-4-chloro-isocoumarins JLK-6 and JLK-2 have been shown to markedly reduce the production of Amyloid beta-peptide (A beta) by Amyloid-beta Precursor Protein (APP) expressing HEK293 cells by affecting the gamma-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor. This suggested that these compounds do not directly inhibit the presenilin-dependent gamma-secretase complex but more likely interfere with an upstream target involved in gamma-secretase-associated pathway. The mechanism of action of these compounds is unknown and there are high fundamental and therapeutical interests to unravel their target. Isocoumarin compounds were previously shown to behave as potent mechanism-based irreversible inhibitors of serine proteases, suggesting that the JLK-directed target could belong to such enzyme family. To get further insight into structure-activity relationships and to develop more potent isocoumarin derivatives, we have synthesized and evaluated a series of isocoumarin analogues with modifications at positions 3, 4 and 7. In particular, the 7-amino group was substituted with either acyl, urethane, alkyl or aryl groups, which could represent additional interaction sites. Altogether, the results highlighted the essential integrity of the 3-alkoxy-7-amino-4-chloro-isocoumarin scaffold for A beta-lowering activity and supported the involvement of a seri ne protease, or may be more generally, a serine hydrolase. The newly reported 7-N-alkyl series produced the most active compounds with an IC50 between 10 and 30 mu M. Finally, we also explored peptide boronates, a series of reversible serine protease inhibitors, previously shown to also lower cellular A beta production. The presented data suggested they could act on the same target or interfere with the same pathway as isocoumarins derivatives. (C) 2012 Elsevier Ltd. All rights reserved.
• PROTEASOME INHIBITORS AND METHODS OF USING THE SAME
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP1660507B2

  公开（公告）日：2017-01-04
• US7576206B2
  申请人：——

  公开号：US7576206B2

  公开（公告）日：2009-08-18

表征谱图